A retrospective, cohort study analysing clinical presentation, risk factors for development of Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis
Latest Information Update: 21 Jan 2021
Price :
$35 *
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- 21 Jan 2021 New trial record